Immunotherapy with peptides

To cite this article: Moldaver D, Larché M. Hundred years of allergen‐specific immunotherapy. Allergy 2011; 66: 784–791.

[1]  F. Simons,et al.  Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. , 1996, International immunology.

[2]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[3]  A. Kay,et al.  Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study , 2004, Allergy.

[4]  M. Larché.  Peptide immunotherapy for allergic diseases , 2007, Allergy.

[5]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[6]  D. Wraith,et al.  Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. , 1998, Novartis Foundation symposium.

[7]  I. Cohen,et al.  Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. , 1997, Journal of autoimmunity.

[8]  J. Greenstein,et al.  Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[10]  C. Berry,et al.  Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Lechler,et al.  Myoblasts fail to stimulate T cells but induce tolerance. , 1994, International immunology.

[12]  A. Kagey‐Sobotka,et al.  Effects of peptide therapy on ex vivo T-cell responses. , 1998, The Journal of allergy and clinical immunology.

[13]  C. Akdis,et al.  Induction of interleukin‐10 and suppressor of cytokine signalling‐3 gene expression following peptide immunotherapy , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  B. Haselden,et al.  Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. , 2001, The Journal of allergy and clinical immunology.

[15]  A. Gaur,et al.  Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. , 1992, Science.

[16]  R. Lechler,et al.  Anergic T cells as suppressor cells in vitro. , 1994, Science.

[17]  D. Wegmann,et al.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Shastri,et al.  Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation , 1986, Nature.

[19]  R. Holmdahl,et al.  Mucosal tolerance and suppression of collagen‐induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184‐198 of bovine type II collagen (CII) expressing a dominant T cell epitope , 1996, Clinical and experimental immunology.

[20]  D. Wraith,et al.  Peptide-based therapeutic vaccines for allergic and autoimmune diseases , 2005, Nature Medicine.

[21]  R. Lechler,et al.  Antigen presentation by keratinocytes induces tolerance in human T cells , 1990, European journal of immunology.

[22]  D. Umetsu,et al.  The safety and efficacy of ALLERVAX CAT in cat allergic patients. , 1999, Clinical immunology.

[23]  M. Atkinson,et al.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes , 1996, The Journal of experimental medicine.

[24]  W. Kuis,et al.  Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Akdis,et al.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.

[26]  C. Akdis,et al.  Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells , 2004, The Journal of experimental medicine.

[27]  B. Haselden,et al.  Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic Reactions , 1999, The Journal of experimental medicine.

[28]  M. Worm,et al.  Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. , 2011, The Journal of allergy and clinical immunology.

[29]  F. Wong,et al.  Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study , 2009, Clinical and experimental immunology.

[30]  C. Heusser,et al.  Allergen‐derived long peptide immunotherapy down‐regulates specific IgE response and protects from anaphylaxis , 2000, European journal of immunology.

[31]  J. Goverman,et al.  T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. , 1994, Science.

[32]  Daniel M. Altmann,et al.  Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression , 2009, The Journal of experimental medicine.

[33]  D. Wraith,et al.  Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. , 1999, International immunology.

[34]  B. Wüthrich,et al.  T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. , 1993, Journal of immunology.

[35]  Dominique Charron,et al.  HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy , 2000, The Journal of Immunology.

[36]  L. Hood,et al.  Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein , 1989, The Journal of experimental medicine.

[37]  R. O’Hehir,et al.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.

[38]  S. Ying,et al.  Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[39]  A. Kay,et al.  T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity , 2005, PLoS medicine.

[40]  F. Spertini,et al.  Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. , 2003, The Journal of allergy and clinical immunology.

[41]  D. Wraith,et al.  Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. , 1993, International immunology.

[42]  M. Larché,et al.  The effect of Fel d 1‐derived T‐cell peptides on upper and lower airway outcome measurements in cat‐allergic subjects , 2005, Allergy.

[43]  A. Kay,et al.  Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects1 , 2001, The Journal of Immunology.

[44]  H. Renz,et al.  Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1 , 1997, Clinical and experimental immunology.

[45]  K. B. Hafner,et al.  Treatment of cat allergy with T-cell reactive peptides. , 1996, American journal of respiratory and critical care medicine.

[46]  E. Matteson,et al.  Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. , 2009, Arthritis and rheumatism.

[47]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[48]  J. Bousquet,et al.  Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. , 1998, The Journal of allergy and clinical immunology.

[49]  H. Fujita,et al.  Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin , 1983, The Journal of experimental medicine.

[50]  P. Tempst,et al.  Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen , 1993, European journal of immunology.

[51]  J. Bonnefoy,et al.  IgE versus IgG4 production can be differentially regulated by IL-10. , 1998, Journal of immunology.

[52]  A. Kay,et al.  Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial , 2002, The Lancet.

[53]  A. Skowera,et al.  Naturally Arising Human CD4 T-Cells That Recognize Islet Autoantigens and Secrete Interleukin-10 Regulate Proinflammatory T-Cell Responses via Linked Suppression , 2010, Diabetes.

[54]  Endy,et al.  LONG-TERM CLINICAL EFFICACY OF GRASS-POLLEN IMMUNOTHERAPY , 2000 .